ALGS
Aligos Therapeutics, Inc.
Next earnings Aug 4, 2026 · consensus $-1.09 EPS, $17.7M rev
Last earnings -5.3% on 2026-05-07
$5.57
▲ 0.00%$5.57▼ -26.23%
over 1Y
L $4.91EODHDH $13.30
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-2.1%
1M-0.5%
3M-16.4%
YTD-39.0%
1Y-26.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Conservative balance sheet (liabilities/equity 0.65x); but revenue fell -39.5% YoY.
Aligos Therapeutics, Inc. shows $2.19M in FY2025 revenue (-39.5% YoY), a -1106.7% net margin, and -45.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $6.19M | $3.61M | $2.19M |
| Gross profit | — | — | — | — | — |
| Operating income | -$128M | -$97.6M | -$88.1M | -$89.2M | -$88.0M |
| Net income | -$128M | -$96.0M | -$87.7M | -$131M | -$24.2M |
| Diluted EPS | — | -$2.25 | -$34.20 | -$20.94 | -$2.45 |
| Net margin | — | — | -1416.2% | -3633.6% | -1106.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$194M
EV / EBITDA—
EV / Sales88.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11.4%
FCF yield-38.9%
Quality & risk
ROIC (est.)-129.8%
Free cash flow-$82.6M
Total debt—
Net cash$18.3M
Altman Z-Score-8.93 distress
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-252026-06-26open ↗SCHEDULE 13DFiling2026-06-24open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗DEFA14AFiling2026-04-29open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEF 14APeriod ending 2026-06-252026-04-29open ↗8-KPeriod ending 2026-04-162026-04-21open ↗8-KPeriod ending 2026-04-142026-04-14open ↗4Period ending 2026-03-092026-03-11open ↗
Frequently asked
- Is Aligos Therapeutics, Inc. (ALGS) a buy?
- ALGS currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.65x); but revenue fell -39.5% YoY.
- What is Aligos Therapeutics, Inc.'s quality score?
- ALGS scores 38.882352941176464/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001799448, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 8:36:42 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.